Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

9 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
No difference in clinical progression between patients infected with the predominant human immunodeficiency virus type 1 circulating recombinant form (CRF) 02_AG strain and patients not infected with CRF02_AG, in Western and West-Central Africa: a four-year prospective multicenter study.
Laurent C, Bourgeois A, Faye MA, Mougnutou R, Seydi M, Gueye M, Liégeois F, Kane CT, Butel C, Mbuagbaw J, Zekeng L, Mboup S, Mpoudi-Ngolé E, Peeters M, Delaporte E. Laurent C, et al. Among authors: mougnutou r. J Infect Dis. 2002 Aug 15;186(4):486-92. doi: 10.1086/341833. Epub 2002 Jul 19. J Infect Dis. 2002. PMID: 12195375
Biological and genetic characteristics of HIV infections in Cameroon reveals dual group M and O infections and a correlation between SI-inducing phenotype of the predominant CRF02_AG variant and disease stage.
Vergne L, Bourgeois A, Mpoudi-Ngole E, Mougnutou R, Mbuagbaw J, Liegeois F, Laurent C, Butel C, Zekeng L, Delaporte E, Peeters M. Vergne L, et al. Among authors: mougnutou r. Virology. 2003 Jun 5;310(2):254-66. doi: 10.1016/s0042-6822(03)00167-3. Virology. 2003. PMID: 12781713 Free article.
Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.
Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, Calmy A, Lactuock B, Nzeusseu V, Mougnutou R, Peytavin G, Liégeois F, Nerrienet E, Tardy M, Peeters M, Andrieux-Meyer I, Zekeng L, Kazatchkine M, Mpoudi-Ngolé E, Delaporte E. Laurent C, et al. Among authors: mougnutou r. Lancet. 2004 Jul 3-9;364(9428):29-34. doi: 10.1016/S0140-6736(04)16586-0. Lancet. 2004. PMID: 15234853 Clinical Trial.
Comparative Immunovirological and Clinical Responses to Antiretroviral Therapy Between HIV-1 Group O and HIV-1 Group M Infected Patients.
Kouanfack C, Unal G, Schaeffer L, Kfutwah A, Aghokeng A, Mougnutou R, Tchemgui-Noumsi N, Alessandri-Gradt E, Delaporte E, Simon F, Vray M, Plantier JC; ANRS 12168 DynaMO Study. Kouanfack C, et al. Among authors: mougnutou r. Clin Infect Dis. 2020 Mar 17;70(7):1471-1477. doi: 10.1093/cid/ciz371. Clin Infect Dis. 2020. PMID: 31063537